ZeNix: Pretomanid, Bedaquiline, and Varied Doses and Durations of Linezolid in Highly Resistant TB

July 18-21, 2021; Virtual
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
Format: Microsoft PowerPoint (.ppt)
File Size: 231 KB
Released: July 26, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert commentary by Dr Babafemi Taiwo on how the latest data from the AMBITION-cm trial will affect the treatment of patients with HIV in Africa

Babafemi Taiwo, MBBS Released: September 17, 2021

Clinical Care Options (CCO) presents Dr. Chien-Ching Hung on results and relevance of the AMBITION-cm trial presented at IAS 2021

person default Chien-Ching Hung, MD, PhD Released: September 2, 2021

Clinical Care Options (CCO) and Dr Daniel R. Kuritzkes present new data from studies of people with HIV and COVID-19, released at the 11th IAS Conference on HIV Science

Daniel R. Kuritzkes, MD Released: August 20, 2021

From Elliott Bosco, PharmD, and Clinical Care Options (CCO), expert commentary on the risks and costs of RSV to older adults in the United States

person default Elliott Bosco, PharmD, PhD Released: August 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.